4//SEC Filing
Petrova Penka 4
Accession 0001062993-21-002674
CIK 0001616212other
Filed
Mar 11, 7:00 PM ET
Accepted
Mar 12, 4:40 PM ET
Size
12.2 KB
Accession
0001062993-21-002674
Insider Transaction Report
Form 4
Petrova Penka
Chief Development Officer
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2021-03-10−2,708→ 86,668 totalExercise: $0.30Exp: 2029-11-07→ Common Shares (2,708 underlying) - Exercise/Conversion
Common Shares
2021-03-10$0.30/sh+2,708$816→ 2,708 total - Exercise/Conversion
Common Shares
2021-03-10$3.35/sh+2,604$8,730→ 5,312 total - Sale
Common Shares
2021-03-10$11.08/sh−5,312$58,857→ 0 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-03-10−2,604→ 52,084 totalExercise: $3.35Exp: 2028-11-08→ Common Shares (2,604 underlying)
Footnotes (4)
- [F1]This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
- [F2]The exercise price of these options is $0.38 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.7925 USD.
- [F3]The exercise price of these options is $4.23 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.7925 USD.
- [F4]25% of the options vest on the one year anniversary of the grant date and the remaining options vest in equal monthly installments over the following 36 months.
Issuer
Trillium Therapeutics Inc.
CIK 0001616212
Entity typeother
Related Parties
1- filerCIK 0001838044
Filing Metadata
- Form type
- 4
- Filed
- Mar 11, 7:00 PM ET
- Accepted
- Mar 12, 4:40 PM ET
- Size
- 12.2 KB